Method of treating diseases using gremlin1 antagonists
AssigneesShanghai Jiao Tong University, Suzhou Transcenta Therapeutics Co., Ltd.
InventorsHe ZHU, Xueming QIAN, Weiqiang GAO, Chaping CHENG, Jinming WANG, Di SUN
Life of this patent
Estimating the term…
Abstract
The present disclosure provides herein treatment methods for GREM1-related disease or condition characterized in deficient in PTEN and/or p53. Also provided by the present disclosure are treatment methods for castration-resistant prostate cancers
Claims44
A method of treating a GREM1-expressing cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of GREM1 antagonist, wherein the cancer is characterized in reduced androgen receptor (AR) signaling.
(canceled)
5-6. (canceled)
A method of increasing sensitivity of an AR-expressing cancer to an androgen deprivation therapy in a subject, comprising administering to the subject a therapeutically effective amount of GREM1 antagonist.
A method of treating a GREM1-related disease or condition characterized in deficiency in PTEN and/or p53 in a subject in need thereof, or inhibiting FGFR1 activation in a subject in need thereof, or inhibiting MAPK signaling in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of GREM1 antagonist.
(canceled)
(canceled)
(canceled)
(canceled)
21-22. (canceled)
(canceled)
26-27. (canceled)
29-30. (canceled)
32-36. (canceled)
38-39. (canceled)
41-42. (canceled)
44-46. (canceled)
50-55. (canceled)
(canceled)
59-60. (canceled)
62-77. (canceled)
Dependencies are inferred from the claim text.